Article
A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors.
Journal of hematology & oncology - 12 Jun 2014
de Vos Sven, Forero-Torres Andres, Ansell Stephen M, Kahl Brad, Cheson Bruce D, Bartlett Nancy L, Furman Richard R, Winter Jane N, Kaplan Henry, Timmerman John, Whiting Nancy C, Drachman Jonathan G, Advani Ranjana
Abstract excerpt
BACKGROUND: Patients with DLBCL who are ineligible for or have relapsed after aggressive salvage chemotherapy have a poor prognosis. CD40 is expressed on multiple B-cell neoplasms including DLBCL and is a potential target for immunotherapy. Dacetuzumab (SGN-40), a non-blocking, partial agonist, humanized IgG1, anti-CD40 monoclonal antibody, has previously demonstrated anti-lymphoma activity in a phase I study....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.